Euroapi (XPAR:EAPI) Accounts Payable & Accrued Expense: €146.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:EAPI Euroapi SA XPAR:EAPI
54 GF Score
Price €0.96
GF Value €2.86
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Euroapi Accounts Payable & Accrued Expense?

Euroapi XPAR:EAPI -2.25% 54 Accounts Payable & Accrued Expense is €146.2 Mil as of Dec. 2025. GuruFocus rates XPAR:EAPI with a GF Score™ of 54/100 and a GF Value™ of €2.86 (Possible Value Trap). The stock has 6 warning signs investors should review.

Euroapi's quarterly accounts payable & accrued expense declined from Dec. 2024 (€143.1 Mil) to Jun. 2025 (€130.5 Mil) but then increased from Jun. 2025 (€130.5 Mil) to Dec. 2025 (€146.2 Mil).

Euroapi's annual accounts payable & accrued expense declined from Dec. 2023 (€203.7 Mil) to Dec. 2024 (€143.1 Mil) but then increased from Dec. 2024 (€143.1 Mil) to Dec. 2025 (€146.2 Mil).

Euroapi Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Euroapi's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Euroapi Accounts Payable & Accrued Expense Chart

Euroapi Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 189.60 250.10 203.70 143.10 146.20

Euroapi Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.70 169.40 143.10 130.50 146.20
XPAR:EAPI
54GF Score
Euroapi SA XPAR:EAPI
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Euroapi Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of €146.2 Mil mean?
Euroapi (XPAR:EAPI) has a Accounts Payable & Accrued Expense of €146.2 Mil as of Dec. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Euroapi and its competitors.
Is Euroapi's Accounts Payable & Accrued Expense too high?
Euroapi's current Accounts Payable & Accrued Expense is €146.2 Mil. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Accounts Payable & Accrued Expense compare to ZTS and UTHR?
Euroapi's Accounts Payable & Accrued Expense of €146.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Euroapi and its competitors. Euroapi's current Accounts Payable & Accrued Expense is €146.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.86, compared to a current price of €0.96 — trading 66.5% below its estimated fair value. The current Accounts Payable & Accrued Expense is €146.2 Mil. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Accounts Payable & Accrued Expense is €146.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Euroapi (XPAR:EAPI) Overvalued in 2026?

Based on GuruFocus' analysis, Euroapi stock appears to be undervalued. The current stock price of €0.96 is trading 66.5% below its estimated GF Value™ of €2.86. GuruFocus considers Euroapi to be Possible Value Trap.

Key valuation signals for XPAR:EAPI:

  • Accounts Payable & Accrued Expense: €146.2 Mil
  • GF Value™: €2.86 vs. price of €0.96 (66.5% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Euroapi Business Description

Other Exchanges EAPIF:USA0EAP:UK940:Germany
Address 32 rue Alexandre Duma, Paris, FRA, 75011
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score

Get the complete analysis for XPAR:EAPI

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price
€2.86
GF Value